Explosive Agents Market Analysis and Financial Projection
The intersection of pharmaceuticals and explosives within the MeSH classification "Explosive Agents" reveals a complex landscape where chemistry meets therapeutic innovation. Below is an analysis of market dynamics and patent trends for drugs in this category, focusing on substances with dual applications in medicine and energetics.
MeSH Classification and Scope
The MeSH term Explosive Agents (D053834) refers to unstable substances producing sudden expansion (explosions) accompanied by heat, pressure, and noise[6][11]. Notably, this excludes laser-induced explosions or epidemiological "outbreaks." Key pharmaceuticals like nitroglycerin are included due to their dual roles: treating angina and serving as explosive precursors[15][16]. MeSH 2022 refined hierarchical relationships, such as moving "sexually transmitted diseases" out of "genital diseases" subcategories[1], improving PubMed search accuracy for related topics.
Market Dynamics
Explosives Industry Growth
Global Market Value: $28.4B in 2022, projected to grow at 4.7% CAGR through 2030[7].
Drivers:
Mining and defense sectors in Asia-Pacific (47% market share)[2][7].
Demand for eco-friendly explosives[7][18].
Key Players: Orica Limited, Dyno Nobel, and Solar Industries India[18].
Pharmaceutical Applications
Nitroglycerin Market: Valued at $492.92M in 2024, driven by cardiovascular therapies and mining explosives[16][18].
High-Potency Drugs: $169.42B in 2023, expanding at 10.7% CAGR due to oncology and neurology innovations[10].
Patent Landscape
Key Expiring Patents (2024–2032)
Drug
Use Case
Patent Expiration
Sales (Peak)
Key Patent Holder
Revlimid
Cancer therapy
Nov 2024
$10.82B (2019)
Celgene Corp[3]
Brilinta
Cardiovascular
Oct 2024
$1.4B (2021)
AstraZeneca[3]
Gonitro (Nitroglycerin)
Angina treatment
Mar 2032
–
G. Pohl Boskamp[17][19]
Notable Innovations:
Stabilized Nitroglycerin Formulations: Patents like US6,500,456 focus on direct-compression tablets with reduced potency loss[19].
Drug Delivery Systems: Explosive-charged injectors (e.g., Patent US11305065) for precise medication expulsion[14].
Competitive and Regulatory Pressures
Generics Surge: Post-2024, drugs like Revlimid and Brilinta face generic competition, accelerating price erosion[3][10].
Safety Challenges: Strict handling protocols for HPAPIs (High-Potency Active Pharmaceutical Ingredients) and nitroglycerin formulations[10][18].
Legal Disputes: Cases like Atlas Powder v. Ireco highlight patent validity battles over explosive compositions, affecting market entry[4].
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
